Zhao et al. [36] showed that PPLN promoted apoptosis in gastric cancer cells through the ERK1/2-EGR1 pathway, and the combination of PPLN and TRAIL resulted in a greater reduction in cell viability compared to individual treatments, suggesting that PPLN increased the TRAIL sensitivity of gastric cancer cells. Here, MAPK3 is linked to gastric cancer.